ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
A clinical-stage cancer company is using artificial intelligence to design its next generation of tumor-targeting drugs. The AI works at the bench to accelerate the development of new therapies. The company announced the integration of AI into its drug discovery pipeline.
Tap to vote and see what everyone thinks.
Summary by ByteBrief